|
Active substance |
Risankizumab |
|
Holder |
AbbVie Belgium SA/NV |
|
Status |
closed |
|
Indication |
treatment of patients with active Crohn's Disease who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious or life-threatening condition |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
21/02/2023 |
Skyrizi
Last updated on